About cabaletta bio inc - CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
CABA At a Glance
Cabaletta Bio, Inc.
2929 Arch Street
Philadelphia, Pennsylvania 19104
| Phone | 1-267-759-3100 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -167,856,000.00 | |
| Sector | Health Technology | Employees | 156 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CABA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.964 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.401 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.396 |
CABA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,076,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CABA Liquidity
| Current Ratio | 2.769 |
| Quick Ratio | 2.769 |
| Cash Ratio | 2.664 |
CABA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -93.445 |
| Return on Equity | -126.978 |
| Return on Total Capital | -120.63 |
| Return on Invested Capital | -123.021 |
CABA Capital Structure
| Total Debt to Total Equity | 24.184 |
| Total Debt to Total Capital | 19.474 |
| Total Debt to Total Assets | 15.914 |
| Long-Term Debt to Equity | 2.569 |
| Long-Term Debt to Total Capital | 2.069 |